Infection with Sporothrix schenckii causes a localized lymphocutaneous disease in the immunocompetent host, while it frequently results in disseminated disease in the immunocompromised patient. There are a growing number of reports of S. schenckii infection in the human immunodeficiency virus (HIV)-infected population, where the disease usually starts as a localized cutaneous lesion and subsequently disseminates. The optimal treatment of systemic sporotrichosis in HIVpositive patients is as yet unknown. This article presents a case report of disseminated sporotrichosis in an HIV-infected patient, a review of the literature, and discussion of treatment options for HIVinfected patients.
Sporotrichosis is caused by Sporothrix schenckii, a dimormixed superficial and perivascular inflammation compatible with an eczematous process. He responded to therapy with phic fungus with a global distribution. It is found in soil [1] and plant material such as sphagnum moss [2] . Sporotrichosis high-dose prednisone and cephalexin, but the lesions subsequently worsened. commonly presents as limited lymphocutaneous lesions but in rare cases is disseminated [3] . The lymphocutaneous form reThree months after presentation he was hospitalized with progressive disease involving an eschar on the distal thumb and sults from cutaneous inoculation and subsequent lymphatic spread. Disseminated disease may be acquired through cutaprominent woody edema of the wrist. The patient underwent debridement of the right thumb, received ceftriaxone, and was neous inoculation, inhalation, or (rarely) ingestion [3, 4] , and it usually results in diffuse cutaneous lesions with involvement referred to our institution for further evaluation.
On presentation a biopsy of a wrist lesion was performed, of one or more additional organ systems.
and high-dose prednisone therapy was given for presumed pyoDisseminated disease most freqently occurs in immunocomderma gangrenosum. One week later, there was worsening of promised individuals such as alcoholics, diabetics [5] , patients the skin lesions over the forearm ( figure 1 ) and further ulcerwith chronic obstructive pulmonary disease [5] or a hematoation and necrosis of the right thumb, with lymphatic streaking logic malignancy, solid organ or bone marrow transplant recipi-(figure 2). Periodic acid -Schiff staining and Grocott-Gomori ents, those receiving corticosteroid therapy, and those infected methenamine -silver nitrate staining of the skin biopsy speciwith HIV [5 -7] . In this report we describe a case of disseminmens revealed numerous cigar-shaped spores consistent with ated sporotrichosis and S. schenckii fungemia occurring as the S. schenckii. initial presentation of AIDS.
The patient was hospitalized and received amphotericin B (0.5 mg/[kgrd]) for disseminated sporotrichosis and ticarcillin/ Case Report clavulanic acid for presumed secondary bacterial infection. He A 47-year-old male presented to our facility for evaluation subsequently tested positive for HIV and had a CD4 cell count of skin lesions. Four months prior to presentation, he was of 9/mm 3 . Skin and blood cultures yielded S. schenckii. evaluated at an outside clinic for a pruritic rash of 3 weeks'
The fungus grew as small white colonies at 30ЊC and later duration. Physical examination revealed multiple scattered became brownish-black with rosette-like clusters. The mycelia psoriasiform eruptions involving his neck, face, scalp, foreconverted to yeastlike forms at 37ЊC, and microscopic examinaarms, and chest. A presumptive diagnosis of pellagra was made, tion also confirmed the presence of cigar-shaped bodies characterand the patient was treated with thiamine, riboflavin, and pyriistic of S. schenckii. A bone scan revealed an increased uptake doxine.
in the right thumb and right wrist, consistent with osteomylitis. Two weeks later, the rash had progressed, and a punch biTwo weeks after initiation of therapy, amphotericin B was opsy of a chest wall lesion revealed spongiotic dermatitis with withdrawn temporarily because of renal toxicity, and daily administration of itraconazole (400 mg) was started. The serum creatinine level normalized, and the patient completed therapy with amphotericin B (total dose, 2.5 g).
Itraconazole is currently the drug of choice for osteoarticular, localized lymphocutaneous, and disseminated sporotrichosis in HIV-seronegative patients. Restrepo et al. reported a clinical and mycological response rate of 100% among 17 patients with lymphocutaneous diseases [20] . Sharkey-Mathis et al., reporting on their experience with the treatment of 27 patients with localized, osteoarticular, or systemic sporotrichosis [5] , noted that 25 patients responded to a 6 -18 month course of itraconazole (200 -400 mg). However, seven patients relapsed within 7 months after completing therapy. The optimal therapy for HIV-infected patients has yet to be determined. Amphotericin B was the initial therapy in eight of the 16 previously reported cases [1, 6 -8, 10, 11, 13, 18] . Five patients' conditions improved after a total dose of 800 -1,900 mg of amphotericin B [1, 6, 8, 11, 13] , while in two patients there was no response [7, 11] . One patient underwent pyoderma gangrenogum; the superficial ulcerations worsened before eye enucleation despite intravenous and intravitreal adminisSporothrix schenckii was identified in skin biopsy specimens.
tration of amphotericin B for endophthalmitis [7] . Four patients had progressive disease and died with sporotrichosis [1, 10, 14, 18] .
Literature Review and Discussion
Administration of itraconazole was successful as initial therapy for three patients [2, 12, 17] . However, one of these patients S. schenckii infection, like Histoplasma capsulatum and Cryptococcus neoformans infections, is an opportunistic mysubsequently developed sporotrichotic meningitis, thought to be related to inadequate blood levels of itraconazole [2] . A cosis in the HIV-infected population. To date, disseminated sporotrichosis has been reported to occur in 16 HIV-infected fourth patient's disease progressed during therapy with ketoconazole, SSKI, and fluconazole, but he responded to itraconazole patients (table 1). All patients presented with diffuse ulcerative skin lesions similar to those in the present case. Involve- [15] . Therapeutic failures have been described in association with SSKI [9] , fluconazole [14] , and ketoconazole [15] . ment of the CNS [2, 13, 14, 18] , eye [7, 10] , joints [1, 6, 9, 10] , spleen [1] , and bone marrow [10] have been previously
Maintenance therapy for sporotrichosis in the HIV-infected population has not been well described. Three patients who reported. However, S. schenckii fungemia is rare, and the present case represents the second report concerning an HIVreceived itraconazole had no documented relapse after 11 -12 months [2, 15, 17] , and a fourth patient was free of disease infected patient. Fifteen of the 16 reported cases involved men (mean age, 38.8 years; range, 22 -71 years). The mean following therapy with itraconazole for an unknown duration [12] . At a 9-month follow-up visit, our patient had no evidence CD4 cell count was 72.8/mm 3 (median, 37.5/mm 3 ; range, 9 -345/mm 3 ; n Å 10) [2, 6, 10, 13 -18] . Sporotrichosis was the of recurrence. initial event leading to a diagnosis of HIV infection in three of the 16 cases [6, 10, 11] .
Therapeutic regimens for sporotrichosis in non-HIV-infected patients are well established. Treatment with saturated solution of potassium iodide (SSKI) for cutaneous sporotrichosis is almost always successful [3] . However, SSKI therapy requires meticulous dosage adjustment and poses a wide range of side effects [20, 21] . Moreover, iodide is ineffective for disseminated disease [21] .
Amphotericin B has been the treatment of choice for osteoarticular and systemic sporotrichosis in HIV-negative patients; it has been associated with cure rates of 50% -80% in pulmonary sporotrichosis, especially if combined with surgical resection [20 -22] . However, the response rate was 74% among patients with osteoarticular sporotrichosis, and there were frequent relapses [23] .
Fluconazole therapy cured 10 (71%) of 14 and 5 (31%) of tively, and appears to be inferior to itraconazole therapy [24] .
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